CommercialPrior AuthMedium impact
Medical Policy Update
Blue Cross Blue Shield of Kansas·KS · Hematology, Rheumatology, Dermatology +3 more·Medical Policy
Effective date
Mar 1, 2024
We identified it
Jun 19, 2026
Summary
Blue Cross Blue Shield of Kansas updated multiple medical and pharmacy policies effective March 1, 2024, including new criteria for Hemophilia A Gene Therapy and various biologic immunomodulators, weight loss agents, and other specialty medications. Billing teams need to review updated prior authorization requirements and medical policies for these specific drug categories.
Action Required
By March 1, 2024: Billing team must review updated medical policies at https://www.bcbsks.com/providers/medical-policies for Hemophilia A Gene Therapy criteria and updated pharmacy policies at https://www.bcbsks.com/providers/precertification-prior-authorization for biologic immunomodulators (IL-1, IL-4, IL-5 inhibitors), Cibinqo, Tezspire, Xolair, Lupus treatments, Opzelura, weight loss agents, and statins. Update prior authorization workflows and medication lists accordingly. Contact BCBSKS provider consultant with questions.